Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | IL1B | P01584 | 1/20 | 0.64 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556664 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL19556665 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL27097754 | 1.00 | CRBN (1.00) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL18270886 | 0.92 | CRBN (0.85) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL30122000 | 0.89 | CRBN (0.81) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL30995305 | 0.89 | CRBN (0.81) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL30002053 | 0.89 | CRBN (0.81) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL27925240 | 0.89 | CRBN (0.80) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL17174015 | 0.87 | CRBN (0.78) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20133033 | 0.87 | CRBN (0.78) | CRBNIKZF3DDB1BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027003-A | PROTAC compound, preparation method thereof and application of PROTAC compound as estrogen receptor degradation agent | 山东大学 | 2024-05-14 | — | — | CN | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| WO-2023030170-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | 标新生物医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | claimed |
| US-20190175575-A1 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORP (US) | 2019-06-13 | — | — | US | claimed |
| EP-1680111-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORP (US) | 2009-07-15 | — | — | EP | claimed |
| EP-1744749-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORP (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1684743-A4 | COMPOSITION AND METHOD FOR TREATING MACULAR DEGENERATION | CELGENE CORP (US) | 2009-02-18 | — | — | EP | claimed |
| EP-2016942-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORPORATION (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1737453-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF SKIN DISEASES OR DISORDERS | CELGENE CORP (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1567157-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMUDULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORP (US) | 2008-06-25 | — | — | EP | claimed |
| US-20040087546-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | CELGENE CORPORATION | 2004-05-06 | — | — | US | claimed |
| WO-2004035064-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-20040029832-A1 | Anticancer agents; angiogenesis inhibitor; side effect reduction | CELGENE CORPORATION | 2004-02-12 | — | — | US | claimed |
| WO-2003097052-A2 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| EP-1040838-B1 | Stable aqueous solution of 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione | GRUENENTHAL GMBH (DE) | 2003-03-26 | — | — | EP | claimed |
| US-20030021763-A1 | Method for the treatment and/or prophylaxis of diseases caused by IL-12 | GRUENENTHAL GMBH. | 2003-01-30 | — | — | US | claimed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | claimed |
| US-6306879-B1 | ISOTONIC GLUCOSE SOLUTION | GRUENENTHAL GMBH (DE) | 2001-10-23 | — | — | US | claimed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029832-A1 | Anticancer agents; angiogenesis inhibitor; side effect reduction | VEGFA, PGF, TEK | CRBN 1357/4885IKZF3 508/4885DDB1 1364/4885 |
| US-20040087546-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases | IL2, MCL1, MYD88 | CRBN 640/4885IKZF3 46/4885DDB1 2323/4885 |
| US-20190175575-A1 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | IL2, PGF, HDGF | CRBN 1262/4885IKZF3 259/4885DDB1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.